García-Ruiz Jose M, Galán-Arriola Carlos, Fernández-Jiménez Rodrigo, Aguero Jaume, Sánchez-González Javier, García-Alvarez Ana, Nuno-Ayala Mario, Dubé Gregory P, Zafirelis Zafiris, López-Martín Gonzalo J, Bernal Juan A, Lara-Pezzi Enrique, Fuster Valentín, Ibáñez Borja
Myocardial Pathophysiology Area, Translational Laboratory for Cardiovascular Imaging and Therapy, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
CIBER de Enfermedades CardioVasculares (CIBERCV), Madrid, Spain.
Basic Res Cardiol. 2017 Mar;112(2):17. doi: 10.1007/s00395-017-0605-6. Epub 2017 Feb 10.
Reperfusion, despite being required for myocardial salvage, is associated with additional injury. We hypothesize that infarct size (IS) will be reduced by a period of bloodless reperfusion with hemoglobin-based oxygen carriers (HBOC) before blood-flow restoration. In the pig model, we first characterized the impact of intracoronary perfusion with a fixed volume (600 ml) of a pre-oxygenated acellular HBOC, HBOC-201, on the healthy myocardium. HBOC-201 was administered through the lumen of the angioplasty balloon (i.e., distal to the occlusion site) immediately after onset of coronary occlusion at 1, 0.7, 0.4, or 0.2 ml/kg/min for 12, 17, 30, and 60 min, respectively, followed by blood-flow restoration. Outcome measures were systemic hemodynamics and LV performance assessed by the state-of-the-art cardiac magnetic resonance (CMR) imaging. The best performing HBOC-201 perfusion strategies were then tested for their impact on LV performance during myocardial infarction, in pigs subjected to 45 min mid-left anterior descending (LAD) coronary occlusion. At the end of the ischemia duration, pigs were randomized to regular reperfusion (blood-only reperfusion) vs. bloodless reperfusion (perfusion with pre-oxygenated HBOC-201 distal to the occlusion site), followed by blood-flow restoration. Hemodynamics and CMR-measured LV performance were assessed at 7- and 45-day follow-up. In modifications of the HBOC-201 procedure, glucose and insulin were included to support cardiac metabolism. A total of 66 pigs were included in this study. Twenty healthy pigs (5 per infusion protocol) were used in the study of healthy myocardium. Intracoronary administration of HBOC-201 (600 ml) at varying rates, including a flow of 0.4 ml/kg/min (corresponding to a maximum perfusion time of 30 min), did not damage the healthy myocardium. Slower perfusion (longer infusion time) was associated with permanent LV dysfunction and myocardial necrosis. A total of 46 pigs underwent MI induction. Compared with regular reperfusion, bloodless reperfusion with pre-oxygenated HBOC-201 alone increased IS. This effect was reversed by enrichment of pre-oxygenated HBOC-201 solution with glucose and insulin, resulting in no increase in IS or worsening of long-term ventricular function despite further delaying restoration of blood flow in the LAD. Bloodless reperfusion with a pre-oxygenated HBOC-201 solution supplemented with glucose and insulin is feasible and safe, but did not reduce infarct size. This strategy could be, however, used to deliver agents to the myocardium to treat or prevent ischemia/reperfusion injury before blood-flow restoration.
再灌注虽然是挽救心肌所必需的,但也会带来额外损伤。我们假设,在血流恢复之前,使用基于血红蛋白的氧载体(HBOC)进行一段时间的无血再灌注可以减小梗死面积(IS)。在猪模型中,我们首先研究了向健康心肌内冠状动脉灌注固定体积(600毫升)的预充氧去细胞HBOC(HBOC-201)的影响。在冠状动脉闭塞开始后,立即通过血管成形术球囊腔(即闭塞部位远端)以1、0.7、0.4或0.2毫升/千克/分钟的速率分别灌注HBOC-201 12、17、30和60分钟,随后恢复血流。通过先进的心脏磁共振(CMR)成像评估全身血流动力学和左心室(LV)功能作为结果指标。然后在45分钟左前降支(LAD)冠状动脉闭塞的猪中,测试表现最佳的HBOC-201灌注策略对心肌梗死期间LV功能的影响。在缺血期结束时,将猪随机分为常规再灌注(仅血液再灌注)组和无血再灌注(在闭塞部位远端用预充氧的HBOC-201灌注)组,随后恢复血流。在7天和45天随访时评估血流动力学和CMR测量的LV功能。在HBOC-201程序的改进中,加入了葡萄糖和胰岛素以支持心脏代谢。本研究共纳入66头猪。20头健康猪(每个输注方案5头)用于健康心肌的研究。以不同速率冠状动脉内给予HBOC-201(600毫升),包括0.4毫升/千克/分钟的流速(对应最大灌注时间30分钟),未损伤健康心肌。较慢的灌注(较长的输注时间)与永久性LV功能障碍和心肌坏死有关。共有46头猪接受了心肌梗死诱导。与常规再灌注相比,单独使用预充氧的HBOC-201进行无血再灌注会增加IS。通过在预充氧的HBOC-201溶液中添加葡萄糖和胰岛素可逆转这种效应,但尽管进一步延迟了LAD血流的恢复,IS并未增加,长期心室功能也未恶化。用添加了葡萄糖和胰岛素的预充氧HBOC-201溶液进行无血再灌注是可行且安全的,但并未减小梗死面积。然而,这种策略可用于在血流恢复前向心肌递送药物以治疗或预防缺血/再灌注损伤。